Deep Brain Stimulation Market Size, Share, Growth by 2030

The deep brain stimulation (DBS) market is projected to expand from US$ 603.52 million in 2022 to US$ 1,155.37 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.5% during this period.

DBS involves the use of a device that delivers electrical impulses to specific brain regions to regulate movement. This technology is widely employed in the treatment of various conditions, including Parkinson's disease, chronic pain, central pain syndrome, epilepsy, and obsessive-compulsive disorder (OCD). By alleviating symptoms such as rigidity, slowness, and mobility issues associated with neurological disorders, DBS plays a crucial role in patient care. The growth of the deep brain stimulation market is primarily driven by the increasing incidence of neurological disorders and a rising preference for minimally invasive surgical options.

Recent technological innovations in DBS include robotic implantation, multi-target stimulation, enhanced microelectrode designs, rechargeable pulse generators, and customized programming. These advancements have led to DBS devices that exhibit fewer adverse effects and greater effectiveness in symptom management for Parkinson's patients compared to conventional treatments. A notable example is Abbott's Infinity Deep Brain Stimulation System, which represents a significant leap in technology, offering a wireless iOS software platform that facilitates efficient and personalized therapy management while minimizing side effects.

Moreover, there has been a surge in FDA approvals for DBS devices aimed at treating conditions such as tremors, severe OCD, and dystonia. For instance, in March 2020, NeuroPace, Inc. received FDA approval for MRI labeling of its RNA system, marking a significant milestone in the field.

In February 2020, MGM Healthcare in Tamil Nadu announced the successful completion of its first DBS procedure for OCD, highlighting the growing acceptance and application of DBS technology. These technological strides are anticipated to create further opportunities for the global deep brain stimulation market throughout the forecast period.

Additionally, advancements in atlases, imaging techniques, and connectomics are enhancing DBS targeting strategies. Innovations in lead design allow for segmented contacts that enable directional stimulation, while improvements in implantable pulse generator (IPG) design lead to smaller, longer-lasting MRI-compatible batteries. Software developments are paving the way for diverse programming strategies that enhance efficacy, reduce stimulation-related side effects, and extend battery life. Brain recognition technologies are expected to provide insights into the physiological mechanisms of DBS, potentially serving as an additional programming strategy. Closed-loop DBS systems can customize stimulation parameters to address individual symptoms, and remote programming options are becoming increasingly feasible and accessible. Ongoing research continues to refine DBS technology for various conditions, with recent studies, such as one from Michigan Technological University in March 2023, exploring neuromorphic computing to enhance the effectiveness and energy efficiency of DBS systems for Parkinson's disease treatment. Consequently, the surge in research and development activities in the DBS domain is likely to further propel market growth in the future.

Insights Based on End Users

The deep brain stimulation market is segmented by end users into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, hospitals held the largest market share and are expected to exhibit the highest CAGR during the forecast period. The growth of the hospital segment is driven by the increasing prevalence of neurological disorders such as Parkinson's and Alzheimer's diseases, which require skilled medical professionals for effective treatment. The number of DBS surgeries performed in hospitals is on the rise. A study titled "Single-Stage Deep Brain Stimulator Placement for Movement Disorders," published in 2021, indicated that approximately 160,000 patients globally have undergone DBS for various neurological and non-neurological conditions, with around 12,000 new patients receiving DBS annually.

Furthermore, DBS surgeries demand high precision and specialized medical care, and the availability of advanced treatment facilities and DBS devices in hospitals is a significant factor attracting patients seeking neurological interventions. Hospitals also employ highly qualified professionals, including experienced neurologists, nurses, and technicians, who collaborate to provide optimal surgical care in a supportive environment. These factors collectively contribute to the anticipated growth of the deep brain stimulation market in the coming years.

The deep brain stimulation market report is based on information from primary and secondary sources, including the World Health Organization (WHO), National Institutes of Health (NIH), and Neurological Health Charities Canada (NHCC).